Global Bacteriophage Therapy Market, by Targeted Bacteria (Escherichia coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, and Others), by Route of Administration (Oral, Topical, and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Increasing prevalence and awareness of antimicrobial-resistant infection is driving adoption of phage therapy for treatment of such infections which is expected to drive the market growth. For instance, according to World Health Organization, in 2016, around 490,000 people developed multi-drug resistant TB globally. This drug resistance has also impacted the management and treatment of other infections such as malaria and HIV. As a result there is increasing inclination among the populace towards non-traditional therapeutics for treating such infections.
Manufacturers are focusing on the development of an effective phage therapy to control such drug resistant infection. Moreover, increasing approvals from drug regulatory authorities for development phage therapy candidates are contributing to growth of the market. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy. The application for the clinical study has been submitted by physician-scientists at the University Of California San Diego School Of Medicine. Following the U.S. FDA approval, the company plans to initiate phase I/II clinical trial study to test AB-SA01, an experimental bacteriophage combination for treatment of participants with ventricular assist devices (VADs) infected by resistant Staphylococcus aureus (S. aureus).
Browse 146 Pages and in-depth TOC on ‘Bacteriophage Therapy Market’- Global Bacteriophage Therapy Market, by Targeted Bacteria (Escherichia coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella and Others), by Route of Administration (Oral, Topical and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the Bacteriophage Therapy market, click the link below:
North America is expected to hold a dominant position in the bacteriophage therapy market over the forecast period, owing to rising prevalence of antibiotic resistant infections in the region. For instance, according to the Centers for Disease Control and Prevention, in 2018, around 2 million people had antibiotic-resistant infection and around 23,000 people died from antibiotic resistant infections each year in the U.S.
Europe is expected to witness growth in the bacteriophage therapy market over the forecast period due to expansion of manufacturing facility for producing bacteriophage therapy, and rising research and development activities by market players in the region. For instance, in June 2015, AmpliPhi BioSciences Corporation, developer of bacteriophage-based antibacterial therapies, received the Good Manufacturing Practices (cGMP) certification from JAZMP, agency of the Republic of Slovenia for Medicinal Products and Medical Devices, for the manufacturing of bacteriophages (Staphylococcus aureus and Pseudomonas aeruginosa) at its facility in Slovenia.
Key Takeaways of the Bacteriophage Therapy Market: